prod:prod_dcx-login
Xpert® Bladder Cancer Monitor
Qualitative monitoring for recurrence in patients previously diagnosed with bladder cancer in around 90 minutes
Sign in or create a MyCepheid account to add items to cart
Test pack size(s)
10 Tests
GXBLAD-CM-CE-10
Qty
Unit price
Subtotal
USD
Product is not available for purchase in your region.
Total
{{currency}}
0
Error adding items to cart. If this error persists, please contact Digital Support
The Need
- After initial diagnosis, the early detection of recurrence is crucial for successful management of bladder cancer patients1,2
- Due to high recurrence rates, frequent follow up by cystoscopy, urine cytology and other methods are required for many years3,4
- Unfortunately, cystoscopy often misses Carcinoma in Situ (CIS) cases and sometimes also misses papillary tumors5
- After invasive cystoscopy procedures, many patients experience pain, bleeding, and infections5,65,6
- Better, non-invasive, and painless methods for monitoring of bladder cancer are needed5-7
1 Campi R et al. Unmet Clinical Needs and Future Perspectives in Non–muscle-invasive Bladder Cancer. Eur Urol Focus. 2018 Jul;4(4):472-4.
2 Su H et al. Hope and challenge: Precision medicine in bladder cancer. Cancer Med. 2019;8:1806–1816.
3 Leal J et al. Economic Burden of Bladder Cancer Across the European Union. Eur Urol 2016. (Mar), 69(3), 438–447.
4 Rink M et al. The current role of circulating biomarkers in non-muscle invasive bladder cancer. Transl Androl Urol 2019;8(1):61-75l.
5 Todenhöfer T et al. Prognostic relevance of positive urine markers in patients with negative cystoscopy during surveillance of bladder cancer. BMC Cancer. 2015 Mar 19;15:155. 15:155.
6 Su H et al. Hope and challenge: Precision medicine in bladder cancer. Cancer Med. 2019;8:1806–1816.
7 Miyake M et al. Emerging biomarkers for the diagnosis and monitoring of urothelial carcinoma. Res Rep Urol 2018:10 251–261
2 Su H et al. Hope and challenge: Precision medicine in bladder cancer. Cancer Med. 2019;8:1806–1816.
3 Leal J et al. Economic Burden of Bladder Cancer Across the European Union. Eur Urol 2016. (Mar), 69(3), 438–447.
4 Rink M et al. The current role of circulating biomarkers in non-muscle invasive bladder cancer. Transl Androl Urol 2019;8(1):61-75l.
5 Todenhöfer T et al. Prognostic relevance of positive urine markers in patients with negative cystoscopy during surveillance of bladder cancer. BMC Cancer. 2015 Mar 19;15:155. 15:155.
6 Su H et al. Hope and challenge: Precision medicine in bladder cancer. Cancer Med. 2019;8:1806–1816.
7 Miyake M et al. Emerging biomarkers for the diagnosis and monitoring of urothelial carcinoma. Res Rep Urol 2018:10 251–261
The Solution
- Xpert® Bladder Cancer Monitor is a non-invasive biomarker test for monitoring NMIBC patients for recurrence in conjunction with other clinical measures
- After testing hundreds of known tumor markers, the five strongest bladder cancer indicator mRNAs were identified and selected
- Xpert Bladder Cancer Monitor is a non-invasive biomarker test with proven clinical sensitivity and specificity for low and high-grade bladder cancer.
- The resulting assay has been extensively validated for bladder cancer monitoring in independent studies8,9,12,13
- Using voided urine, the test is easy to perform within 90-minutes and uses self-contained cartridges and an automated system8-10
- The assay was developed to have high sensitivity and a high negative predictive value, especially for aggressive high-grade tumors
- The test can be performed in any size urology lab and does not require a traditional PCR lab set up.
- Every cartridge contains three controls for reliable results
- Samples are stable for up to 7 days in Xpert® Urine Transport Reagent at 2–28 °C10
- External controls* are available11
8 Wallace E et al. Development of a 90-Minute Integrated Noninvasive Urinary Assay for Bladder Cancer Detection. J Urol 2018 Mar;199(3):655-662.
9 Van Valenberg, FJP et al. Prospective Validation of an mRNA-based Urine Test for Surveillance of Patients with Bladder Cancer. Eur Urol 2019;75:853-60.
10 Xpert® Bladder Cancer Monitor Package Insert 301-5933, Rev. E Sep 2021
11 Controls can be ordered at Maine Molecular Quality Controls http://www.mmqci.com/products/c104.html
12 D’Elia C et al. Diagnostic predictive value of Xpert Bladder Cancer Monitor in the follow-up of patients affected by nonmuscle invasive bladder cancer. J Clin Pathol 2018;0:1–5.
13 Pichler R et al. Increased accuracy of a novel mRNA-based urine test for bladder cancer surveillance. BJU Int. 2018 Jan;121(1):29-37
9 Van Valenberg, FJP et al. Prospective Validation of an mRNA-based Urine Test for Surveillance of Patients with Bladder Cancer. Eur Urol 2019;75:853-60.
10 Xpert® Bladder Cancer Monitor Package Insert 301-5933, Rev. E Sep 2021
11 Controls can be ordered at Maine Molecular Quality Controls http://www.mmqci.com/products/c104.html
12 D’Elia C et al. Diagnostic predictive value of Xpert Bladder Cancer Monitor in the follow-up of patients affected by nonmuscle invasive bladder cancer. J Clin Pathol 2018;0:1–5.
13 Pichler R et al. Increased accuracy of a novel mRNA-based urine test for bladder cancer surveillance. BJU Int. 2018 Jan;121(1):29-37
The Impact
- A non-invasive bladder cancer test can reduce patients’ anxiety and pain6
- Non-invasive monitoring tests can complement traditional methods and might help some patients avoid invasive procedures7
- Reducing anxiety for patients about testing discomfort can improve monitoring compliance and ensure early detection of bladder cancer recurrence14
- Aggressive high-grade tumors can be ruled out with high certainty due to the high negative predictive value,reassuring patients and their doctors
- 90 min time-to-result facilitates patient management
6 Su H et al. Hope and challenge: Precision medicine in bladder cancer. Cancer Med. 2019;8:1806–1816.
7 Miyake M et al. Emerging biomarkers for the diagnosis and monitoring of urothelial carcinoma. Res Rep Urol 2018:10 251–261
14 Biardeau X, et al.Prospective evaluation of anxiety, pain, and embarrassment associated with cystoscopy and urodynamic testing in clinical practice. Can Urol Assoc J.2017 Mar-Apr; 11(3-4): 104–110.
7 Miyake M et al. Emerging biomarkers for the diagnosis and monitoring of urothelial carcinoma. Res Rep Urol 2018:10 251–261
14 Biardeau X, et al.Prospective evaluation of anxiety, pain, and embarrassment associated with cystoscopy and urodynamic testing in clinical practice. Can Urol Assoc J.2017 Mar-Apr; 11(3-4): 104–110.
Related Products
Xpert BCR-ABL Ultra
Sensitive and quantitative monitoring of BCR-ABL mRNA in patients with chronic myelogenous leukemia (CML)
Xpert Bladder Cancer Detection
Detection of the presence of bladder cancer in patients with hematuria in around 90 minutes
Xpert FII & FV
30-Minute Test for Genetic Risk of Thrombosis
Xpert Breast Cancer STRAT4
Standardized breast cancer ESR1/PGR/ERBB2/MKi67 mRNA biomarker assessment in less than two hours